Unveiling shared therapeutic targets and pathological pathways between coronary artery disease and major depressive disorder through bioinformatics analysis.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Depressive Disorder, Major*/drug therapy ; Depressive Disorder, Major*/genetics ; Depressive Disorder, Major*/metabolism ; Coronary Artery Disease*/genetics ; Coronary Artery Disease*/drug therapy ; Computational Biology*/methods ; Protein Interaction Maps*; Humans ; Gene Regulatory Networks ; Molecular Docking Simulation ; Signal Transduction ; Gene Expression Profiling

Coronary artery disease (CAD) is a predominant cardiovascular condition influenced by risk factors, with an emphasis on major depressive disorder (MDD). However, the shared mechanisms and therapeutic targets for CAD and MDD remain incompletely comprehended. Functional enrichment analyses were conducted to investigate the pathways associated with the differentially expressed genes (DEGs) in the CAD and MDD datasets. Hub genes were identified utilizing the Protein-Protein Interaction network and Cytoscape software. The single sample gene set variation analysis was applied to assess immune cell infiltration in the CAD and MDD datasets. Weighted gene co-expression network analysis and molecular biological experiments were executed to evaluate these hub genes. Molecular docking was conducted to identify drug candidates targeting these hub genes. The overlapping DEGs between the CAD and MDD datasets were mainly enriched in the Herpes simplex virus 1 infection and the NF-kappa B signaling pathways. CDC42, NDUFB3, and TXN were validated within the eigengenes of the blue module, which exhibited a significant association with the CAD phenotype. The drug candidate GS-9620 was identified as a potential protective agent against both disorders. In conclusion, CDC42, NDUFB3, and TXN held potential as molecular biomarkers and therapeutic targets for the simultaneous treatment of CAD and MDD.
Competing Interests: Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: All animal experiments were approved by the Medical Ethics Committee of Union Hospital Affiliated to Huazhong University of Science and Technology. All experiments were conducted in compliance with the United Kingdom Animals (Scientific Procedures) Act 1986 and the American Veterinary Medical Association Guidelines for the Euthanasia of Animals (2020) and the ARRIVE guidelines.
(© 2024. The Author(s).)

Psychosom Med. 2003 Sep-Oct;65(5):729-37. (PMID: 14508013)
Front Immunol. 2023 Dec 07;14:1287136. (PMID: 38130716)
Biochem Biophys Res Commun. 2017 Aug 26;490(3):719-725. (PMID: 28642137)
Vaccines (Basel). 2023 Jan 28;11(2):. (PMID: 36851164)
J Transl Med. 2013 Feb 07;11:31. (PMID: 23391324)
J Inflamm Res. 2023 Jul 26;16:3169-3184. (PMID: 37525634)
Molecules. 2023 Jan 22;28(3):. (PMID: 36770779)
Int J Geriatr Psychiatry. 2007 Jul;22(7):613-26. (PMID: 17236251)
Curr Top Med Chem. 2023;23(22):2158-2171. (PMID: 37138428)
Hepatol Commun. 2024 Mar 4;8(3):. (PMID: 38437062)
Oxid Med Cell Longev. 2022 Aug 5;2022:8917947. (PMID: 36035208)
Heart. 2002 Nov;88(5):521-3. (PMID: 12381649)
Eur Heart J. 2006 Dec;27(23):2763-74. (PMID: 17082208)
Oxid Med Cell Longev. 2015;2015:898393. (PMID: 26078821)
Biomolecules. 2023 Apr 20;13(4):. (PMID: 37189442)
Curr Top Med Chem. 2023;23(6):415-425. (PMID: 36567285)
Bioinformatics. 2022 Aug 2;38(15):3844-3846. (PMID: 35751589)
BMC Syst Biol. 2014;8 Suppl 4:S11. (PMID: 25521941)
Innovation (Camb). 2021 Jul 01;2(3):100141. (PMID: 34557778)
J Affect Disord. 2024 Jul 1;356:190-203. (PMID: 38604455)
Am J Cardiol. 1993 Aug 15;72(5):428-33. (PMID: 8394643)
Circulation. 2005 Jun 28;111(25):3481-8. (PMID: 15983262)
PLoS One. 2019 Oct 24;14(10):e0222818. (PMID: 31647818)
Nat Rev Cardiol. 2017 Mar;14(3):145-155. (PMID: 27853162)
Hum Mol Genet. 2014 Sep 1;23(17):4569-80. (PMID: 24722204)
Psychosom Med. 2003 May-Jun;65(3):362-8. (PMID: 12764208)
Psychosom Med. 2003 Mar-Apr;65(2):201-10. (PMID: 12651987)
JAMA. 2003 Jun 18;289(23):3106-16. (PMID: 12813116)
Cardiovasc Res. 2021 Jan 21;117(2):450-461. (PMID: 31977009)
Front Immunol. 2022 Jul 28;13:962393. (PMID: 35967341)
Front Immunol. 2022 Oct 28;13:984480. (PMID: 36389763)
Clin Psychol Rev. 2008 Feb;28(2):288-306. (PMID: 17601644)
Int J Mol Sci. 2019 Sep 04;20(18):. (PMID: 31487867)
J Vis Exp. 2022 Aug 9;(186):. (PMID: 36036590)
J Cell Physiol. 2019 Aug;234(10):16812-16823. (PMID: 30790284)
J Affect Disord. 2024 Mar 15;349:86-100. (PMID: 38199392)
J Clin Invest. 2016 May 2;126(5):1630-9. (PMID: 27135880)
Nucleic Acids Res. 2018 Jul 2;46(W1):W60-W64. (PMID: 29912392)
J Clin Med Res. 2020 Jul;12(7):409-414. (PMID: 32655734)
BMC Cardiovasc Disord. 2023 Oct 7;23(1):496. (PMID: 37805479)
Virulence. 2021 Dec;12(1):2670-2702. (PMID: 34676800)
Nat Protoc. 2006;1(3):1559-82. (PMID: 17406449)
Atherosclerosis. 2010 Sep;212(1):351-5. (PMID: 20594554)
BMC Genomics. 2023 Apr 25;24(1):216. (PMID: 37098514)
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt C):322-328. (PMID: 28442424)
Arch Gen Psychiatry. 2009 Apr;66(4):387-96. (PMID: 19349308)
Front Immunol. 2023 May 09;14:1184126. (PMID: 37228596)
Biol Psychiatry. 2004 Jan 1;55(1):1-9. (PMID: 14706419)
JAMA. 2002 Aug 14;288(6):701-9. (PMID: 12169073)
Asian J Androl. 2006 Sep;8(5):589-94. (PMID: 16752004)
Eur J Pharmacol. 2022 May 15;923:174901. (PMID: 35364070)
Psychol Bull. 1987 May;101(3):343-62. (PMID: 3602244)
Trends Genet. 2015 Mar;31(3):128-39. (PMID: 25648499)
BMC Psychiatry. 2014 Dec 24;14:371. (PMID: 25540022)
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 10;88:320-326. (PMID: 30138646)
Apoptosis. 2023 Oct;28(9-10):1423-1435. (PMID: 37369808)
Front Endocrinol (Lausanne). 2022 Aug 29;13:986384. (PMID: 36105394)
J Neurooncol. 2018 Jan;136(1):41-50. (PMID: 29079956)
Drug Discov Today. 2020 Jul;25(7):1270-1276. (PMID: 32404275)
Phys Med Biol. 2018 Mar 29;63(7):07TR01. (PMID: 29512515)
Front Immunol. 2024 Apr 02;15:1368904. (PMID: 38629070)
Biometrics. 2022 Jun;78(2):421-434. (PMID: 33704769)
Mol Biol Rep. 2021 Feb;48(2):1181-1191. (PMID: 33566225)
Front Neurosci. 2023 Jul 05;17:1192766. (PMID: 37476838)
BMC Bioinformatics. 2008 Dec 29;9:559. (PMID: 19114008)
J Immunol. 2018 Apr 1;200(7):2313-2326. (PMID: 29440353)
Respir Res. 2018 Feb 08;19(1):27. (PMID: 29422044)
Front Immunol. 2022 Oct 19;13:1015882. (PMID: 36341378)
Int Immunopharmacol. 2022 Dec;113(Pt A):109390. (PMID: 36330918)
J Clin Psychiatry. 2020 Mar 17;81(2):. (PMID: 32220155)
J Zhejiang Univ Sci B. 2017 Apr.;18(4):277-288. (PMID: 28378566)
Am J Cardiol. 1992 Nov 1;70(13):1228-31. (PMID: 1414957)
Braz J Med Biol Res. 2023 Sep 08;56:e12855. (PMID: 37703110)
Chemistry. 2020 Aug 12;26(45):10175-10184. (PMID: 32097513)
Am J Prev Med. 2002 Jul;23(1):51-61. (PMID: 12093424)
Br J Psychiatry. 2007 Jun;190:460-6. (PMID: 17541103)
Life Sci. 2023 Oct 1;330:122007. (PMID: 37544377)
Cardiovasc Res. 2017 Jan;113(1):30-39. (PMID: 27864310)
Nat Rev Immunol. 2002 Oct;2(10):725-34. (PMID: 12360211)
J Inflamm Res. 2024 Jun 25;17:4093-4104. (PMID: 38948198)
J Transl Med. 2022 Sep 5;20(1):399. (PMID: 36064568)
Front Immunol. 2021 Aug 09;12:716469. (PMID: 34434197)
Sci Transl Med. 2021 Jun 23;13(599):. (PMID: 34162752)
Transl Psychiatry. 2021 Nov 17;11(1):593. (PMID: 34789750)

WJ2018H0120 the 2018 General Project of Hubei Provincial Health and Family Planning Commission

Keywords: Coronary artery disease; Hub gene; Immune cell infiltration; Major depressive disorder; Molecular docking

Date Created: 20241126 Date Completed: 20241126 Latest Revision: 20241130

20250114

PMC11599718

10.1038/s41598-024-80920-2

39592804